Tren-AQ 75 is an aqueous suspension of ultra-micronized un-esterified trenbolone base for IM administration suitable only when extremely rapid increases in serum trenbolone are required. Serum response varies widely with depth and location of IM injection and characteristics of the suspension. Serum trenbolone levels will increase within 1 hour of IM administration. Trenbolone is an anabolic steroid with significant anabolic and androgenic effects.Trenbolone promotes significant increases in strength, muscle anabolism, appetite, and aggression and has been demonstrated to reduce body fat.
Males: Trenbolone use may be indicated in patients where substantial weight gain and increases in musculature are required for patient health after substantial losses of body mass especially in instances where caloric intake is limited and other anabolic therapies have previously failed. The physician and patient must consider the risks of therapy versus the potential benefits.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
Trenbolone binds strongly to the androgen receptor and its action is generally considered to derive therefrom. It produces significant anabolism even during periods of limited caloric restriction. The literature offers conflicting reports of the susceptibility of trenbolone to aromatize into estrogen or reduce to a dihydrotestosterone derivative.Rat studies have suggested that trenbolone may exert effects typically associated with dihydrotestosterone through a non-DHT pathway potentially with direct receptor action. It has been suggested that trenbolone may reduce cortisol production through an indeterminate pathway of activity upon glucocorticoid receptors.
Trenbolone has been demonstrated to promote muscle growth, appetite, aggression, and the production of red blood cells through the production of erythropoietic stimulating factor. Trenbolone is suspected of selective binding of the progesterone receptor potentially acting as both an agonist and an antagonist. It has been suggested that trenbolone is capable of binding to the prolactin receptor. Thus serum progesterone and serum prolactin levels should be monitored during treatment and if elevated anti-progesterone and anti-prolactin agents should be considered.
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, nephritis, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Neurological: Increased libido, headache, anxiety, depression, extreme agitation, irritability, and generalized paresthesia. Trenbolone may cause severe aggressive behavior.
Other: Serum lipid changes, hypertension, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
May alter metabolism of cyclosporins.
Avoid other hepatotoxic medications.
Patients with known hypersensitivity to any ingredients in this product.
Patients with known or suspected carcinomas of the breast, testis, or prostate.
Patients with severe heart disease, liver disease, or kidney disease or with a history of epilepsy.
Products containing androgens should not be used in women as they may cause virilization and fetal harm.
Trenbolone may increase aggressiveness and cause psychiatric changes. These changes may onset more rapidly and with greater effect from trenbolone aqueous suspension than a trenbolone ester. At the first sign of psychiatric changes discontinue use of trenbolone and contact a physician.
Women, children and elderly males should not use.
Trenbolone should be used with extreme caution and with the lowest dosage and duration of treatment necessary for clinical response pursuant to the advice of a qualified physician.
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Due to its hepatotoxicity, liver functions should be monitored. Discontinue on signs of jaundicing.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Progesterone, Prolactin, Blood Pressure.
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 50 - 75mg IM injected 2 to 3 times per week for a duration limited to 4 weeks under care of physician.
(75mg/ml) - 5 ampules of 1ml each.
Store in a cool dry place between 15 - 25oC. Protect from light.
Shake well before each use.
PRODUCT AUTHENTICATION :
NEWS / EVENTS
Magnum Pharmaceuticals Authentication
Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.
Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.
Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.